^
Association details:
| Biomarker: | HER-2 elevation + TMB-L |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | HER2 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1489P - Liquid biopsy forecasted disease progression and indicated therapeutic improvement for gastric cancer patients receiving HER2-targeted regimen
Published date:
09/14/2020
Excerpt:
40 advanced GC patients receiving HER2-targeted therapy were recruited...Specifically, ERBB2-high-TMB-high patients didn't respond to HER2-targeted therapy as vigorously as ERBB2-high-TMB-low patients (ORR=45.5% vs 70.6%, DCR=63.6% vs 100%, mPFS=7.13 vs 3.07 month).
